圣达生物(603079) - 2021 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2021 was ¥189,577,266.40, a decrease of 12.41% compared to the same period last year[5] - The net profit attributable to shareholders for Q3 2021 was ¥16,081,305.40, down 67.17% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥12,864,292.50, reflecting a decline of 72.88% compared to the previous year[6] - Basic earnings per share for Q3 2021 were ¥0.09, down 68.97% year-on-year[6] - The net profit for the year-to-date period was ¥63,971,067.69, a decrease of 68.08% compared to the same period last year[5] - Total operating revenue for the first three quarters of 2021 was CNY 579,712,707.21, a decrease of 13.06% compared to CNY 666,879,888.27 in the same period of 2020[19] - Net profit for the third quarter of 2021 was CNY 59,720,628.14, a decline of 69.7% from CNY 197,048,165.72 in Q3 2020[21] - Earnings per share (EPS) for the third quarter was CNY 0.37, down from CNY 1.19 in the same quarter of the previous year[22] Cash Flow and Investments - The cash flow from operating activities for the year-to-date period was ¥76,282,066.80, showing a decrease of 69.34%[6] - Cash flow from operating activities for the first three quarters was CNY 76,282,066.80, a decrease of 69.4% compared to CNY 248,816,246.60 in the same period of 2020[25] - Investment cash inflow totaled CNY 304,590,156.75, down from CNY 360,536,090.95 in the previous year[25] - The net cash flow from investing activities was -$153,359,186.68, a significant decrease compared to $1,190,832.87 in the previous year[26] - The cash outflow from investing activities was $457,949,343.43, compared to $359,345,258.08 in the prior year[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,735,248,659.76, an increase of 2.02% from the end of the previous year[6] - Current assets totaled RMB 921,831,516.24, compared to RMB 881,145,953.09 in the previous year, reflecting a growth of approximately 4.3%[16] - Total liabilities reached RMB 410,378,611.28, up from RMB 375,803,333.30, marking an increase of approximately 9.2%[17] - Short-term borrowings increased to RMB 145,525,188.58 from RMB 115,229,518.56, reflecting a rise of about 26.3%[17] - The total cash and cash equivalents at the end of the period were $328,835,747.55, down from $494,472,658.72 year-over-year[26] Shareholder Information - The company reported a total of 18,939 common shareholders at the end of the reporting period[11] - The company's retained earnings increased to CNY 415,600,650.56, up from CNY 411,545,718.17 in the previous year[21] - Minority interests decreased to CNY 16,177,781.60 from CNY 20,428,221.15 in the same period of 2020[21] Operational Challenges - The company experienced a significant decline in profitability due to reduced sales revenue and increased costs[9] - Total operating costs increased to CNY 524,778,475.97, up 19.5% from CNY 438,888,177.67 in the previous year[19] - The company has not disclosed any new product developments or market expansion strategies in this report[14] Other Financial Metrics - The weighted average return on equity decreased to 1.24%, down 2.58 percentage points from the previous year[6] - The company reported a significant increase in accounts payable, which rose to RMB 70,061,779.05 from RMB 91,543,324.75, a decrease of approximately 23.5%[17] - Cash and cash equivalents decreased to RMB 354,458,601.75 from RMB 461,312,425.40, representing a decline of about 23.2%[15] - Accounts receivable increased to RMB 127,864,942.95 from RMB 112,883,790.15, showing an increase of approximately 13.3%[16] - Inventory rose to RMB 183,870,245.64 from RMB 167,942,379.48, indicating an increase of about 9.5%[16] - The company has not adopted the new leasing standards for the current year[27]